Abstract. Mounting evidence supports a role for DNA methylation in the pathogenesis of leukemia; however, there no overview of these results in the Chinese population. The present study performed a comprehensive meta-analysis to establish candidate genes with an altered methylation status in Chinese leukemia patients. Eligible studies were identified through searching the National Center of Biotechnology Information PubMed and Wanfang databases. Studies were pooled and overall odds ratios with corresponding confidence intervals were calculated. A total of 4,325 leukemia patients and 2,010 controls from 94 studies on 53 genes were included in this meta-analysis, and 47 genes were found to be aberrantly methylated in leukemia patients. A further subgroup meta-analysis by leukemia subtype demonstrated that hypermethylation of 5 genes, namely cyclin-dependent kinase (CDKN)2A, DNA-binding protein inhibitor-4, CDKN2B, glioma pathogenesis-related protein 1 and p73, contributed to the risk of various subtypes of leukemia. In addition, a strong association between CDKN2A and leukemia was identified in Chinese (P<0.00001) but not in European patients. The aberrantly methylated genes identified in the present meta-analysis may help elucidate the mechanisms underlying the development of leukemia in Chinese patients.
Introduction
Leukemia is a complex hematological malignancy, characterised by clonal proliferation of malignant hematopoietic stem cells in the blood and bone marrow (1) , with a total of 350,000 new cases and 25,700 deaths annually (2) . Genetic as well as environmental factors have been suggested to be associated with leukemia, including trisomy 21, gender, cytotoxicity of anticancer drugs, exposure to benzene and ionising radiation (3) (4) (5) (6) . Leukemia is a heterogeneous disease that comprises acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). ALL accounts for 81% of childhood leukemia cases, while CLL and AML frequently occur in adults (7) .
Racial and ethnic disparities have been identified in the expression of leukemia-related genes, the clinical outcome and the mortality rate of leukemia (8) (9) (10) (11) (12) . These disparities are likely due to a combination of genetic, environmental and socioeconomic factors (13) , which may affect epigenetic changes. Epigenetics, such as DNA methylation, have been shown to play an important role in cancer susceptibility (14, 15) . Therefore, DNA methylation studies may help elucidate these racial and ethnic disparities in leukemia patients.
Aberrant DNA methylation of genes has been shown to be associated with a large number of human malignancies (16, 17) . Although a recent meta-analysis by our group identified significant associations between a number of aberrantly methylated genes and leukemia (18) , the majority of the studies published in the Chinese language are overlooked. Thus, the aim of the present study was to focus on the association of aberrant DNA methylation and leukemia susceptibility in the Chinese population and to investigate ethnic differences in DNA methylation using subgroup meta-analyses.
Materials and methods

Selection of studies.
A systematic literature search was performed through the National Center for Biotechnology Information (NCBI) PubMed and Wanfang literature databases, updated until July 10, 2014. The search was performed using the keywords 'leukemia' and 'methylation'. Potentially relevant articles were identified by their titles and abstracts, followed by selection of eligible studies based on full-text analysis.
Case-control studies on gene methylation in Chinese leukemia patients containing sufficient information on methylation to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) were considered to be eligible. A flow chart of the study selection process is shown in Fig. 1 .
Data extraction.
The following characteristics were extracted from each eligible study: First author's name, year of publication, disease category and methylation status of cases and controls. All the studies included were reviewed by three authors (D.J., Y.S. and C.X.). For genes with methylation data in other populations, the corresponding data were retrieved and subjected to meta-analyses for comparison with the Chinese population.
Statistical analysis. Review Manager 5.0 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used for the meta-analysis. The ORs and 95% CIs were calculated to evaluate the association between gene methylation and leukemia. Heterogeneity of the included studies was assessed using I 2 statistics (19) . When there was significant heterogeneity (I 2 >50%), the random-effects model was used to calculate the overall OR and 95% CI; otherwise, the fixed-effects model was applied (20) .
Results
Eligible studies. As shown in Fig. 1, 1 ,477 potentially relevant studies were identified for initial review from the NCBI PubMed and Wanfang literature databases. A total of 1,380 studies were excluded (1,036 irrelevant studies, 227 non-case-control studies and 117 studies with insufficient data). Finally, a total of 94 studies (61 studies on ALL, 76 on AML, 11 on CLL, 31 on CML and 3 other studies on leukemia), were included in the present meta-analysis (31, 38, . A total of 53 genes were identified among 4,325 leukemia patients and 2,010 control subjects, of which 19 were reported by only 1 study, 15 by 2 studies and 19 by ≥3 studies (Tables I and II) . For 47 of these 53 genes, aberrant methylation was proved to be significantly associated with leukemia. Meta-analysis of the association between CDKN2B methylation and leukemia. The meta-analysis of the association between CDKN2B methylation and leukemia included 24 studies comprising 463 cases and 302 controls (Fig. 3) . Meta-analysis of the association between DNA-binding protein inhibitor-4 (ID4) methylation and leukemia. A total of 10 studies were included in the ID4 methylation analysis (Fig. 4) . The meta-analysis revealed that ID4 methylation was a risk factor for leukemia (P<0.00001; OR=70.08; 95% CI: 24.12-203.64 Meta-analysis of the association between p73 methylation and leukemia. The meta-analysis of p73 methylation included 7 case-control studies (Fig. 6) . The results revealed that hypermethylation of p73 was associated with an increased risk of leukemia (P<0.00001; OR=17.07; 95% CI: 6.20-47.02). In addition, the results showed that p73 methylation was a risk factor for AML (P=0.002; OR=20.83; 95% CI: 3.01-143.95) and ALL (P<0.00001; OR=15.92; 95% CI: 4.87-52.07), while there was no significant difference between the two subtypes.
Meta-analysis of the association between cyclin-dependent
Subgroup meta-analysis of gene methylation and leukemia by ethnicity. Based on our previous study (18) , a further subgroup meta-analysis by ethnicity was performed for CDKN2A and CDKN2B methylation. Hypermethylation of CDKN2A and CDKN2B was associated with an increased risk of leukemia in Chinese populations (P<0.00001), while only CDKN2B was associated with leukemia in Europeans (P=0.007) (Figs. 7 and 8). Of note, there was a significant difference between European and Chinese populations regarding the association of CDKN2A and CDKN2B methylation with leukemia (P<0.00001 and P=0.02, respectively).
Discussion
In the present study, eligible studies were retrieved from the NCBI PubMed and Wanfang literature databases and a systematic meta-analysis was performed to investigate the association between the methylation status of 53 genes and leukemia, with the aim of providing evidence regarding the role of gene methylation in the pathogenesis of leukemia, particularly in different leukemia subgroups and ethnic groups.
Aberrant gene promoter methylation, occurring in almost every tumor type, is one of several mechanisms of gene inactivation (21) . Promoter hypermethylation of tumor suppressor genes often contributes to loss of function and cancer development (22, 23) . One potential mechanism for hypermethylation-induced silencing is changing the structure of specific binding sites for certain transcriptional regulators (24) . Epigenetic silencing of genes by promoter hypermethylation is associated with the loss of tumor suppression, increasing tumor severity and reducing patient survival (25) . The present meta-analysis revealed significant changes in the methylation status of the CDKN2A, CDKN2B, ID4, GliPR1, p73 and Wilms' tumor 1 (WT1) genes in the major types of leukemia (21, 23, (26) (27) (28) .
Numerous studies revealed that CDKN2A and CDKN2B methylation is frequent during malignant transformation (29) (30) (31) Table II . List of methylated genes and associated case-control studies. 
Cases (n) Controls (n) -------------------------------------------------------------------------
Cases (n) Controls (n) ----------------------------------------------------------------------
according to differences in the first exons and control the progression of cells from the G1 to the S phase (29, 125) . The present meta-analysis demonstrated that hypermethylation of CDKN2A and CDKN2B are risk factors for leukemia. According to the subgroup meta-analysis, hypermethylation of CDKN2A was significantly associated with AML, ALL and CLL, but not with CML, while CDKN2B hypermethylation was significantly associated with AML, ALL and CML. The lack of association of CDKN2A with CML may be attributed to the limited sample included in the the meta-analyses (CML power, 6.4%; and CLL power, 6.3%). The ID4 protein is a member of the dominant-negative basic helix-loop-helix transcription factor family that lacks DNA-binding activity (126) and has a tumor suppressor function. The promoter of ID4 was reported to be consistently methylated to various degrees in CLL and a univariate analysis demonstrated that increased promoter methylation of ID4 was correlated with shortened patient survival (127) . Previous studies also reported that ID4 gene promoter hypermethylation was highly correlated with acute leukemia and may reflect the malignant degree of AML (128, 129) . The results of the present meta-analysis demonstrated that methylation of the ID4 gene was associated with an increased risk of leukemia, particularly CML.
The GliPR1 protein, encoded by the GliPR1 gene, has been identified as an epigenetically regulated tumor suppressor in prostate cancer and AML. GliPR1 may serve as a marker for monitoring disease activity in AML patients during therapy (61, 130) . Moreover, GliPR1 expression was found to be significantly increased in bone marrow samples of AML patients, while being markedly reduced in ALL, unchanged in myelodysplastic syndrome and marginally decreased in CLL and CML (131) . The present meta-analysis identified hypermethylation of the GliPR1 promoter as a risk factor for leukemia in the Chinese population. p73, a homologue of the p53 tumor suppressor family, is involved in neurogenesis, sensory pathways, immunity, inflammation and tumorigenesis (132) . Furthermore, p73 hypermethylation resulting in its deactivation is frequently observed in malignant lymphoproliferative disorders, particularly ALL (21) . In line with these results, the present meta-analysis also identified p73 hypermethylation as a risk factor for leukemia in the Chinese population.
The WT1 gene encodes a zinc finger transcription factor that is an RNA-binding protein with important roles in the development of several organs and tissues. WT1 has been reported to have tumor suppressor as well as oncogenic activity; however. the reasons and mechanisms underlying these opposing functions remain to be fully elucidated (133) . The present study demonstrated that WT1 hypermethylation played a protective role against the progression of leukemia.
Previous studies have reported that the risk of hematological malignancies varies significantly among different ethnic groups (9, 13, 134, 135) . The present meta-analysis indicated that there was no association between CDKN2A methylation and the risk of leukemia (P=0.16) in Europeans, while a significant association was observed in Chinese populations (P<0.00001). A significant difference in the association of CDKN2A methylation with leukemia was observed between European and Chinese populations (P<0.00001). This result may provide molecular evidence to guide future individualization of chemotherapy for leukemia, although further research is required to elucidate the precise nature of the ethnic differences in leukemia. Of note, the present meta-analysis had certain limitations. First, the numbers of the studies regarding each gene and leukemia subtype were uneven. For certain leukemia subtypes, only a few studies on certain genes were available. The lack of association of the methylation status of certain genes with several leukemia subtypes may have been due to a lack of statistical power of the respective studies, so that the negative results must be interpreted with caution. Furthermore, a language bias was present, as only studies written in Chinese and English were included.
In conclusion, the present meta-analysis revealed that aberrant DNA methylation of the promoters of 47 genes was associated with leukemia. Further subgroup meta-analysis revealed 5 hypermethylated genes (CDKN2A, CDKN2B, ID4, GliPR1 and p73) in various leukemia subtypes. In addition, a difference in the association of CDKN2A and CDKN2B hypermethylation with leukemia was identified between Chinese and European populations. The results of the present study may enhance the current understanding of the association of DNA methylation with leukemia in the Chinese population.
